PureTech Health
| Company type | Public |
|---|---|
| Industry | Healthcare |
| Founded | 2005 |
| Headquarters | Boston, United States |
Key people | Christopher Viehbacher (Chairman) Daphne Zohar (CEO) |
| Products | Medicines |
| Revenue |  $15.6 million (2022)[1] |
| $(197.8) million (2022)[1] | |
 $(37.4) million (2022)[1] | |
| Website | puretechhealth |
PureTech Health is a biotech company listed on the London Stock Exchange and included in the FTSE 250 Index. It was founded in 2005 by Daphne Zohar.[2] PureTech Health develops medicines to treat serious diseases. It has subsidiary companies focused on various therapeutic areas, including neuropsychiatric disorders, weight management, cognitive disorders, autoimmune diseases, and inflammatory diseases.[3] They also have their own pipeline of therapeutics in immunology, lymphatics, and oncology.[4]
References
[change | change source]- ↑ 1.0 1.1 1.2 "Annual Results 2022". PureTech Health. Archived from the original on 28 April 2023. Retrieved 28 April 2023.
- ↑ "PureTech's long view on biopharma". Boston Globe. 26 August 2015. Archived from the original on 16 August 2019. Retrieved 16 August 2019.
- ↑ "PureTech Health affiliate Vedanta Biosciences awarded $5.8m grant". Sharecast. 5 December 2019. Archived from the original on 14 December 2019. Retrieved 14 December 2019.
- ↑ "PureTech Licenses Glyph Lymphatic Technology". FT. 29 August 2017. Archived from the original on 15 January 2020. Retrieved 14 December 2019.